Author

Jenna H. Rannikko

University of TurkuORCID 0000-0002-9506-9099Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:mouse· 1

Frequent Co-Authors

Maija HollméniD· 3 shared Ilkka KoskivuoiD· 2 shared Pia BoströmiD· 2 shared Rita TurpiniD· 2 shared Ábris Ádám BendesiD· 1 shared Anil K. Thotakura· 1 shared Anita N. KumariiD· 1 shared Arno YlitaloiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Maija HollménORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

YAP/TEAD drives treatment-induced adaptive immunosuppression in EGFR-mutant lung cancer

Meija Honkanen, Jonas Baumgarten, Nikol Dibus, Jenna H. Rannikko, Miloš Gojković, Paloma Cejas, Yingtian Xie, Zsuzsanna Ortutay, Johannes A. M. Merilahti, Mari Tienhaara, Iman Khani Farahani, Steffen Boettcher, Pasi Antero Janne, Otto Kauko, Raphael A. Nemenoff, , Kari J. Kurppa

This study shows that DTP cells in EGFR-mutant lung cancer drive immunosuppression through YAP/TEAD activity, and co-targeting YAP/TEAD improves EGFR TKI therapy efficacy.

bioRxiv · Jan 24, 2026 · PreprintCancer Biology

Secreted Clever-1 Modulates T Cell Responses and Impacts Cancer Immunotherapy Efficacy

Stuart Prince, Miro Viitala, Riikka Sjöroos, Ábris Ádám Bendes, Jenna H. Rannikko, Daniel A. Patten, Ilaria di Benedetto, Rita Turpin, Arno Ylitalo, Laura Tyni, Carlos R. Figueiredo, Pia Boström, Ilkka Koskivuo, Tiina Annamaria Salminen, Shishir Shetty, Maija Hollmén

This study identifies a secreted form of Clever-1 that suppresses T cell responses and reduces anti-PD-1 efficacy in cancer, suggesting it as a therapeutic target and biomarker.

Theranostics · Jun 23, 2025Peer-reviewedImmunology

Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses

Rita Turpin, Karita Peltonen, Jenna H. Rannikko, Ruixian Liu, Anita N. Kumari, Daniel Nicorici, Moon Hee Lee, Minna Mutka, Panu E. Kovanen, Laura Niinikoski, Tuomo J Meretoja, Johanna Mattson, Petrus Järvinen, Kanerva Lahdensuo, Riikka Järvinen, , Juha T. Klefström

The paper evaluates immunomodulatory drug responses in patient-derived tumor explant models of breast and renal cancer, finding reproducible gene expression and cytokine changes across models.

OncoImmunology · Feb 17, 2025Peer-reviewedImmunology